Coeliac disease

Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium

Retrieved on: 
Friday, October 21, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CET, Autoimmune disease, Multiple sclerosis, ICDS, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Assessment, Patient, Coeliac disease, Symposium, Food, Immune tolerance, Liver, Fast Track, Clinical trial, Gliadin, Safety, 2009 Davis Cup, Pharmaceutical industry, Tolerability

Celiac disease is a serious autoimmune disease triggered by ingestion of gluten for which there are no approved therapeutic treatments available.

Key Points: 
  • Celiac disease is a serious autoimmune disease triggered by ingestion of gluten for which there are no approved therapeutic treatments available.
  • Based on the results from the Phase 1 trial, Anokion is preparing to initiate a global Phase 2 trial of KAN-101 in patients with celiac disease.
  • These data suggest that our KAN-101 product candidate could be the first disease-modifying approach to treating celiac disease.
  • KAN-101 has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of celiac disease.

Undercover Snacks Announces Launch into Costco Eastern Canada

Retrieved on: 
Wednesday, October 19, 2022
Dark, EAST, Rite Aid, CVS, CAD, Albertsons, Coeliac disease, Milk, Loblaws, Airline, Kroger, CEO, Whole Foods Market, Amazon (company), Grocery store, Fast food, Publix, Costco, Snack, Undercover operation, United, Eastern Canada

EAST HANOVER, N.J., Oct. 19, 2022 /PRNewswire/ -- Undercover Snacks, the rapidly growing NJ-based manufacturer of unbelievably delicious, crazy-crispy chocolate snacks that are secretly better for you, announced today that its best-selling, plant-based Dark Chocolate + Sea Salt Quinoa Crisps have launched in approximately 70 Costco Wholesale locations across Eastern Canada. This launch follows Undercover's success in recent US Costco rotations across the Southeast and San Francisco Bay Area.

Key Points: 
  • The innovative woman-owned snack manufacturer has launched its best-selling Dark Chocolate + Sea Salt Crisps across Eastern Canada Costco Wholesale locations.
  • EAST HANOVER, N.J., Oct. 19, 2022 /PRNewswire/ -- Undercover Snacks, the rapidly growing NJ-based manufacturer of unbelievably delicious, crazy-crispy chocolate snacks that are secretly better for you, announced today that its best-selling, plant-based Dark Chocolate + Sea Salt Quinoa Crisps have launched in approximately 70 Costco Wholesale locations across Eastern Canada.
  • "We are extremely excited to be expanding our distribution both in Costco and across Canada, following our two recent successful US Costco rotations," said Diana Levy, Founder, Co-Owner and CEO of Undercover Snacks.
  • Undercover Snacks is a covert operation, crafting delicious chocolate snacks that are secretly better for you.

Anokion Announces $35 Million Equity Investment from Pfizer

Retrieved on: 
Tuesday, October 18, 2022
Health, Other Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Immunology, DDW, Inflammation, Autoimmune disease, Multiple sclerosis, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Assessment, Patient, Coeliac disease, Food, Immune tolerance, Liver, Fast Track, Gliadin, Pharmaceutical industry, Pfizer

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative.
  • Separately, Anokion and Pfizer have entered into an agreement to leverage Pfizers development expertise and capabilities in support of the continued clinical development of KAN-101, Anokions lead candidate for the treatment of individuals with celiac disease.
  • We are excited about these agreements with Pfizer as they provide us with important resources and expertise to advance our KAN-101 clinical program and our earlier-stage pipeline, said Deborah Geraghty, Ph.D., chief executive officer of Anokion.
  • Based on favorable findings, Anokion is preparing to initiate patient dosing in a Phase 2 clinical trial in the second half of 2022, supported by Pfizer.

Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center at Stony Brook Children's Hospital

Retrieved on: 
Tuesday, October 11, 2022
CDC, Education, Disease, Hospital, Bed, Certification, YouTube, Organization, Family, Patient, Coeliac disease, Research, Twitter, Single person, Instagram, Program, Multimedia, History, HIV, Duchenne muscular dystrophy, PPMD, Muscle, Infant, APRN, Travel, FDA, John F. Cotton Corporate Wellness Center, PNP, View, Medicine, Duchenne, Facebook, Hope

WASHINGTON, Oct. 11, 2022 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced the expansion of their renowned Certified Duchenne Care Center (CDCC) Program with the certification of Stony Brook Children's Hospital, in Stony Brook, New York. This is an exciting addition to the CDCC Program as it is not only the first certification on Long Island and in the NYC metropolitan area, but brings comprehensive, multidisciplinary Duchenne clinical care to a heavily populated, but underserved region.

Key Points: 
  • WASHINGTON, Oct. 11, 2022 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , announced the expansion of their renowned Certified Duchenne Care Center (CDCC) Program with the certification of Stony Brook Children's Hospital , in Stony Brook, New York.
  • PPMD's Certified Duchenne Care Center Program supports standardized, comprehensive care and services for all people living with Duchenne.
  • Part of Stony Brook Medicine, Stony Brook Children's has more than 180 pediatric specialists in 30 specialties.
  • It is home to the nation's first Pediatric Multiple Sclerosis Center and also offers a Level 3 Neonatal Intensive Care Unit, Duchenne Muscular Dystrophy Center, Celiac Disease and Gluten Sensitivity Center, Healthy Weight and Wellness Center, Cystic Fibrosis Center, Pediatric Hematology/Oncology Program, Pediatric Cardiology Program, Pediatric HIV and AIDS Center.

New United European Gastroenterology report reveals major health and economic impact of digestive diseases across Europe

Retrieved on: 
Sunday, October 9, 2022
News, Gross domestic product, Prevalence, Smoking, Policy, Degenerative disease, Gastritis, Mortality, GDP, Obesity, Incidence, Liver, Gastroesophageal reflux disease, EU, UEG, Pancreatitis, Chronic liver disease, Coeliac disease

These include chronic liver diseases, pancreatitis, gastroesophageal reflux disease, gastritis, vascular intestinal disorders and coeliac disease in children.

Key Points: 
  • These include chronic liver diseases, pancreatitis, gastroesophageal reflux disease, gastritis, vascular intestinal disorders and coeliac disease in children.
  • In addition, the incidence and mortality rates for all digestive cancers combined have increased by 26% and 17% respectively in the period 2000-2019.
  • The report identifies that digestive diseases affect over 300 million people across Europe and the Mediterranean area and that the associated economic costs are substantial.
  • Unfortunately, despite their substantial prevalence and global impact, many digestive diseases are still poorly understood and attract relatively little attention from either a policy or funding perspective".

CAULIPOWER Reinvents Another American Favorite With First-Ever Chickpea & Cauliflower Coated Chicken Nuggets

Retrieved on: 
Wednesday, September 21, 2022
Coeliac disease, Health, Walmart, Club, LOS, LOVE, Sodium, Growth, Chicken nugget, Edible, Program, Sam, Taste, Chicken fingers, Parent, GLOBE, American Heart Association, Sam's Club, Fast food, Poultry

LOS ANGELES, Sept. 21, 2022 (GLOBE NEWSWIRE) -- CAULIPOWER, the maker of the #1 Cauliflower Crust Pizza and #1 Gluten-Free Pizza in the US, is officially launching All Natural1 Chicken Nuggets. CAULIPOWER’s latest innovation is made with all natural1 white meat chicken raised with no antibiotics ever, with a veggie coating made of chickpea & cauliflower, making them the ONLY chickpea and cauliflower coated chicken nuggets on the market!

Key Points: 
  • CAULIPOWERs latest innovation is made with all natural1 white meat chicken raised with no antibiotics ever, with a veggie coating made of chickpea & cauliflower, making them the ONLY chickpea and cauliflower coated chicken nuggets on the market!
  • CAULIPOWERs new All Natural1 Chicken Nuggets are gluten free always and free from artificial colors, flavors, and preservatives, trans fats, and added sugars.
  • Since we launched our All Natural1 Chicken Tenders in 2019, our CAULIPOWER Crew has been asking us to reinvent another childhood favorite the chicken nugget, says Gail Becker, Founder of CAULIPOWER.
  • Our new All Natural1 Chicken Nuggets are made with premium, all natural1 chicken and a veggie-packed coating thats perfectly crispy and gluten-free.

Bari Consulting Group, Celiac Journey and Gluten Free Finds Release Top Policy Priority for the White House Conference on Hunger, Nutrition and Health: Reduce Diet-Related Disease By Labeling Gluten as a Major Food Allergen

Retrieved on: 
Tuesday, September 20, 2022
Advocacy Group Opinion, Fitness & Nutrition, Public Policy, Government, Other Health, Food, Beverage, White House, Federal Government, General Health, Health, Retail, Public Safety, Pillar, Degenerative disease, Coeliac disease, Institute, Risk assessment, World News, Milk, Integration, Policy, Review, Risk, Food industry, FDA, Food, Prevalence, Hordeum, World, World Health Organization, Nutrition, Hope, Gluten-free diet, Intention, Wheat, United Nations, Crustacean, Division, National Strategy for Trusted Identities in Cyberspace, Food safety, Bari, Government, Egg, Physician, Food and Agriculture Organization, Public health, World News Tonight, Technology, Food security, White House Conference on Food, Nutrition, and Health, White House, Process, Committee, Conference, Fear, White House conference, Agriculture, Medical device, Codex, Hunger, Gluten, Health

In advance of the White House Conference on Hunger, Nutrition, and Health on September 28, 2022 ( #WHConfHungerHealth ), Bari Consulting Group, Celiac Journey and @GlutenFreeFinds_pa released a comprehensive report which includes their top policy objective that has the potential to dramatically improve nutrition, reduce food insecurity and reduce diet-related disease for millions of Americans with Celiac Disease.

Key Points: 
  • In advance of the White House Conference on Hunger, Nutrition, and Health on September 28, 2022 ( #WHConfHungerHealth ), Bari Consulting Group, Celiac Journey and @GlutenFreeFinds_pa released a comprehensive report which includes their top policy objective that has the potential to dramatically improve nutrition, reduce food insecurity and reduce diet-related disease for millions of Americans with Celiac Disease.
  • The intention of the Bari Report is to inform the National Strategy of the White House Conference with the recommendation of naming of Gluten as a Major Food Allergen and requiring that Gluten be labeled on all packaged foods.
  • Part 1: Review and validation of Codex priority allergen list through risk assessment.
  • The Bari Report to the FDA (Docket: FDA-2021-N-0553) is available here, www.celiacjourney.com/whconf

NIMA Partners and empowerDX, a division of Eurofins, Announce Strategic Partnership to Promote New Celiac Disease Genetic Risk Test

Retrieved on: 
Thursday, September 15, 2022
Coeliac disease, Laboratory, COVID-19, Twitter, NIMA, Brain, FDA, MD, HLA, LinkedIn, Degenerative disease, Small intestine cancer, Partnership, Women's health, Instagram, Solution, Grammatical mood, Genetic testing, Life, Arthralgia, Health minister, Ecosystem, COVID-19 testing, Awareness, Immune system, Men's Health, Disease, Eurofins Scientific, Medicine, Flour, Vaccine, Pharmaceutical industry, Facebook

KANSAS CITY, Mo., Sept. 15, 2022 /PRNewswire/ -- NIMA Partners, the makers of Gluten Sensor and Gluten Capsules for the detection of gluten in food particles, announced today that they have entered into an exclusive partnership with Clinical Enterprise, Inc. (d/b/a empowerDX) to cross-promote a new, revolutionary, at-home Celiac Risk Gene Test.

Key Points: 
  • The Celiac Gene Risk Test, from empowerDX, measures three HLA gene markers (HLA-DQ2 + HLA-DQ8 + DQA1*05) using two simple mouth swabs.
  • "Those who suffer from Celiac Disease and Gluten Intolerance deserve all the support they can get, which is why this partnership is so important," said NIMA Partners CEO, David DellaFave.
  • Travis Wilkes, MD, the Medical Director at empowerDX said, "The empowerDX & NIMA Partners collaboration will help spread celiac disease awareness, improve access to risk testing, and provide solutions for living well with celiac disease.
  • More than 99% of people who develop celiac disease carry one of the genetic variants identified by empowerDX's new test.

empowerDX, a Subsidiary of Eurofins Scientific, and NIMA Partners Announce Strategic Partnership to Improve Celiac Disease Awareness and Support

Retrieved on: 
Wednesday, September 14, 2022
Science, Women, Biotechnology, Research, Pharmaceutical, Men, Health, Consumer, Coeliac disease, Laboratory, Child, COVID-19, Lists of diseases, Twitter, NIMA, Risk, FDA, Disease, LinkedIn, Degenerative disease, Partnership, Instagram, Solution, Genetic testing, Life, Enterprise, Health minister, Ecosystem, COVID-19 testing, Awareness, Education, View, Eurofins Scientific, Flour, Pharmaceutical industry, Vaccine, Facebook

This partnership is part of NIMA Partners continued commitment to increase the level of service we offer those who suffer from Celiac Disease and Gluten Intolerance, said NIMA Partners CEO, David DellaFave.

Key Points: 
  • This partnership is part of NIMA Partners continued commitment to increase the level of service we offer those who suffer from Celiac Disease and Gluten Intolerance, said NIMA Partners CEO, David DellaFave.
  • Celiac disease is a genetic autoimmune condition where the bodys immune system attacks the small intestine when gluten is consumed.
  • More than 99% of people who develop celiac disease carry one of the genetic variants identified by empowerDXs Celiac Risk Gene Test.
  • Collaborating with NIMA Partners, empowerDX is helping to educate families about genetic testing for celiac disease.

73% of Celiac Disease Patients Still Exposed to Gluten Every Year, Highlighting Need for a Cure on National Celiac Disease Awareness Day

Retrieved on: 
Tuesday, September 13, 2022
Sarah Ruhl, Coeliac disease, Awareness, The Harris Poll, Murray, Bast, Infertility, Degenerative disease, Mayo Clinic Proceedings, Cancer, Diagnosis, Research, Mystery, Franziska Brantner, Brain damage, Fear, Disease, Dentistry, Flour

PHILADELPHIA, Sept. 13, 2022 /PRNewswire/ -- A recentsurvey of the celiac disease community by Beyond Celiac , the leading catalyst for a celiac disease cure, reveals the ongoing challenges those with the disease are facing on National Celiac Disease Awareness Day, Sept. 13, and the overwhelming desire for new treatments and a cure.

Key Points: 
  • PHILADELPHIA, Sept. 13, 2022 /PRNewswire/ -- A recentsurvey of the celiac disease community by Beyond Celiac , the leading catalyst for a celiac disease cure, reveals the ongoing challenges those with the disease are facing on National Celiac Disease Awareness Day, Sept. 13, and the overwhelming desire for new treatments and a cure.
  • The only current celiac disease treatment, which is only partially effective, is to follow a strict, gluten-free diet.
  • "We need real therapies and a cure for celiac disease so that those with the disease can live full lives and eat without fear."
  • Less hidden celiac disease but increased gluten avoidance without a diagnosis in the United States.